I am the director for clinical research in gynecologic oncology, as well as the co-director of the gynecologic oncology phase I program. I also serve as the ORIEN physician liaison for The Ohio State University Comprehensive Cancer Center. I am active nationally as a committee member for the NCI Gynecologic Cancer Steering Committee’s Ovarian Task Force, NRG Oncology (Ovarian Cancer and Developmental Therapeutics Groups), the Society of Gynecologist Oncology and the American Society of Clinical Oncology. My passion for improving the care of patients with gynecologic cancers and my expertise in ovarian cancer resulted in my appointment to the panel of the National Comprehensive Cancer Network (NCCN) Guidelines for Ovarian Cancer, where I continue as an active participant.
As a member of the Translational Therapeutics Program at the OSUCCC – James, my research is focused on identifying novel and innovative therapies for gynecologic cancers. I have designed, coordinated and published on all levels of clinical trials to include phase I, II and III studies with a special interest in novel compounds. I continue to work to improve the therapies (novel techniques/targets/immune therapy) as well as identify patients who would benefit (or not benefit) from different treatment options in ovarian and uterine cancer (specifically high-risk histologies) while minimizing side effects.